Agents that target these abnormalities, including IDH inhibitors (e.g., ivosidenib and enasidenib), FLT3 inhibitors (e.g., midostaurin, gilteritinib, quizartinib, and sorafenib), and others, have offered an opportunity for remission with AML harboring targetable mutations[17,18]. Here, IDH1 is linked to acute myeloid leukemia.